Tier 2 — strong

Acute nicotinamide riboside supplementation increases human cerebral NAD⁺ levels in vivo

Nanga RPR, Wiers CE, Elliott MA, Wilson NE, Liu F, Cao Q, Swago S, Jacobs PS, Armbruster R, Reddy D, Baur JA, Witschey WR, Detre JA, Reddy R

Magnetic resonance in medicine 2024 92; 6; 2284-2293

Bibliography

PubMed: PMID 39044608
PubMed Central: PMC11436296
DOI: 10.1002/mrm.30227
Funding: Indexed grant support includes NHLBI NIH HHS, NIA NIH HHS, NIBIB NIH HHS. The complete funding declaration is not specified in the accessible abstract.
Competing interests: A complete competing-interest declaration is not specified in the accessible publication information.

Design	Human pharmacokinetic study
Model	Human participants
Sample	10 healthy volunteers
Intervention	Single oral NR dose of 900 mg
Duration	Brain spectroscopy 4 hours after dosing
Endpoints	Cerebral NAD+ spectroscopy; test–retest reliability

Cerebral NAD+ measured with high-field spectroscopy increased after an acute oral NR dose.

Cerebral NAD+ measured with high-field spectroscopy increased after an acute oral NR dose.

Small, acute study without a parallel placebo group; target engagement is not evidence of better cognition or treatment of neurological disease.

Editorial review

Last verified 22 October 2026